Filing Details

Accession Number:
0001127602-12-007673
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-02-23 16:40:41
Reporting Period:
2012-02-22
Filing Date:
2012-02-23
Accepted Time:
2012-02-23 16:40:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
882796 Biocryst Pharmaceuticals Inc BCRX Biological Products, (No Disgnostic Substances) (2836) 621413174
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1452635 S Yarlagadda Babu 4505 Emperor Blvd.
Suite 200
Durham NC 27703
Vp Drug Discovery No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-02-22 5,865 $1.18 58,603 No 4 M Direct
Common Stock Acquisiton 2012-02-22 1,226 $1.04 59,829 No 4 M Direct
Common Stock Acquisiton 2012-02-22 23,821 $1.20 83,650 No 4 M Direct
Common Stock Disposition 2012-02-22 30,912 $4.22 52,738 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Emp. Stock Option (Right to Buy) Disposition 2012-02-22 5,865 $0.00 5,865 $1.18
Common Stock Emp. Stock Option (Right to Buy) Disposition 2012-02-22 1,226 $0.00 1,226 $1.04
Common Stock Emp. Stock Option (Right to Buy) Disposition 2012-02-22 23,821 $0.00 23,821 $1.20
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2003-08-05 2012-08-05 No 4 M Direct
0 2003-12-11 2012-12-11 No 4 M Direct
76,179 2010-03-02 2019-03-02 No 4 M Direct
Footnotes
  1. The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.26. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.